Tuesday, June 9, 2026, 1:00–2:00 PM ET In this webinar, we will examine how immune recognition after allogeneic HCT can influence leukemia relapse and disease progression. The session will highlight the clinical relevance of HLA loss of heterozygosity (LOH), approaches used for its detection, and how LOH findings may support transplant strategies, including considerations for donor selection in subsequent transplantation.
Webinar presenter Alberto Cardoso Martins Lima, PhD, Clinical consulting scientist in histocompatibility, specializing in allogeneic hematopoietic cell transplantation (HCT) at IGEN/AFIP São Paulo and CHC/UFPR in Curitiba, Brazil
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, June 24, 2026, 12:00–1:00 PM ET Hear an expert discuss the expanded clinical utility of HER2 IHC scoring in metastatic breast cancer and its impact on your practice
Webinar presenter Michelle Shiller, DO, AP, CP, MGP, FACP, Baylor University Medical Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, July 15, 2026, 1:00-2:00 PM ET Hear an expert discuss how to integrate Kappa and Lambda in situ hybridization testing into your standard hematopathology workflow to accurately assess B-cell and plasma cell clonality. You will also gain the skills to recognize testing pitfalls in challenging reactive versus neoplastic proliferations and apply ancillary tools to resolve complex cases.
Webinar presenter Xiaojun Wu, MD, PhD, Assistant professor, Director of Hematopathology Section at NCR of Johns Hopkins Medicine Department of Pathology, SOM at Johns Hopkins University
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Every month CAP TODAY brings essential news to all key decision makers—clinical lab managers and administrators, pathologists, physicians, lab directors, and supervisory technologists responsible for clinical laboratory purchases.
This news includes advances in tests and equipment, trends in management and clinical operation, regulatory changes, and finance, plus news about the laboratory improvement programs of the College of American Pathologists.
READERS: 52,500
All key decision-makers, no excess
Pathologists: 14,000
Lab Directors: 11,000
Laboratory Administrators
and Managers: 10,000
Laboratory Section Heads and
Supervisors: 15,000
Laboratory Executives in IDNs and Large Health Systems: 2,500
SERVICES TO ADVERTISERS
AD-MARK: In 2026, CAP TODAY will test ads in the April and November issues.
This service provides valuable insight into how our readers engage with ads, articles, and different sections of the magazine. This feedback offers advertisers a clear picture of their ad’s performance. Respondents assess each advertisement based on how helpful it is in understanding the product, providing key data to refine messaging and optimize impact.
Signet Advertising Study in the February, June, and September issues.
An advertisement in the February, June, and September issue will be included in the Signet Advertising Study to examine multiple facets of readers’ attitudes to ads—includes verbatim comments and measures of attention, appeal, and gauges interest in your company and products. Now providing direct leads for advertisers in the issue.